Vycor Medical (VYCO) Price to Sales (2013 - 2026)

Vycor Medical (VYCO) has reported Price to Sales for 14 consecutive years, with 5.59 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 36.1% year-over-year to 5.59 in Q2 2026; TTM through Jun 2026 was 1.29, a 47.01% decrease from a year earlier, with the FY2025 full-year figure at 2.15, up 46.21% from the prior year.
• Price to Sales was 5.59 for Q2 2026 at Vycor Medical, down from 6.55 in the prior quarter.
• Over five years, Price to Sales peaked at 13.66 in Q2 2022 and troughed at 4.59 in Q1 2025.
• A 5-year average of 8.49 and a median of 8.59 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales plunged 50.52% in 2023 and jumped 87.2% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 10.79 in 2022, then decreased by 21.53% to 8.47 in 2023, then plunged by 39.4% to 5.13 in 2024, then surged by 87.2% to 9.61 in 2025, then slumped by 41.86% to 5.59 in 2026.
• The last three Price to Sales figures came in at 5.59 (Q2 2026), 6.55 (Q1 2026), and 9.61 (Q4 2025), per Business Quant data.